Teva Announces Launch Of The First And Only Generic Version Of Sandostatin LAR Depot, In The U.S.
Teva Announces Launch Of The First And Only Generic Version Of Sandostatin LAR Depot, In The U.S.
Teva宣佈在美國推出第一款也是唯一的Sandostatin LAR Depot仿製藥版本。
-
This first-to-market launch showcases Teva's proven strengths in complex generic formulations and enhances Teva's strategic goal of sustaining a generic powerhouse.
- Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome.
- 這次首次上市展示了梯瓦在複雜通用配方方面的實力，增強了梯瓦持續成爲通用藥強大力量的戰略目標。
- 奧曲唑酸肽可用於注射懸液，適用於治療肢端肥大症和類癌綜合症所致的嚴重腹瀉。
PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of Sandostatin1 LAR Depot, in the United States.
紐交所及TASE證券代碼：TEVA）的美國附屬公司梯瓦製藥於2024年10月01日宣佈，在美國推出了Sandostatin1 LAR Depot的首個唯一通用版本。
Octreotide acetate for injectable suspension (the generic version of Sandostatin LAR Depot) is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome. Please see the below for more information.
奧曲唑酸肽可用於注射懸液（Sandostatin LAR Depot的通用版本），適用於治療肢端肥大症和類癌綜合症所致的嚴重腹瀉。更多信息請見下文。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。